Articles
MDoutlook®: Delivers Precision Intelligence
It’s never been more challenging than in today’s dynamic climate for your new products or brands to achieve their full potential. Measuring and communicating success is critical. Implementing the right tracking of your product is imperative for monitoring, interpreting and impacting key performance indicators for your market, your products and
Continue Reading
Rising stars are the upcoming, bright, talented, technophile medical experts in specialist therapy areas. Their outlook on emerging treatment approaches gives an important insight into future treatments. These emerging leaders are often digital influencers as well, making them even more relevant in the current times. Identifying and engaging with the
Continue Reading
MDoutlook, a precision intelligence leader specializing in life science strategies, recently launched Lumineer™, an extension of the company’s proven suite of ThoughtLeader identification solutions. The latest offering in MDoutlook’s thought leadership and precision intelligence services, Lumineer delivers several material differentiators that set it apart from other online Life Science resources.
Continue Reading
The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little
Continue Reading
With ASCO announcing their inaugural virtual program last week and ahead of other major oncology and hematology conferences (such as EHA) moving online, client appetite for planning their activities have not abated in hiring us to measure impact of their data announcement activity in the current “new norm”. Have you
Continue Reading
Having recently named the 2020 leaders in oncology and ImmunoOncology, our latest release from our annual Corporate Leadership report reveals the key attributes oncologists view as driving successful leadership in IO. “Products” and “R&D/Product Pipeline” are the two most important aspects driving oncologists’ view of Corporate Leadership. The top five
Continue Reading
In our latest annual series exploring corporate leadership (in oncology and IO), oncologists shared their views to reveal BMS (and Celgene), Merck & Co and Roche / Genentech as dominant in oncology and ImmunoOncology. Today’s corporate leaders dominated in 2019 with oncologist preferences showing consistency in their ranking companies (year
Continue Reading
Most life science companies strategize to engage ThoughtLeaders with the majority of clients deploying engagement strategies during Phase 3 / launch. A small number target influential ThoughtLeaders earlier (pre-clinical/pre-launch) building long-term valuable relationships (‘brand ambassadors”) within scientific and physician communities. Along the product journey, MDoutlook empowers clients by engaging experts
Continue Reading
Over the past year, we have helped more clients than ever with timely critical input to their business. Through our validated and active community of cancer treaters and ThoughtLeaders, we engaged 87,000 physicians worldwide. We have helped clients make confident business decisions in the following ways. Precision ThoughtLeader identification and
Continue Reading
Identifying the right experts is often lengthy and challenging for biopharmaceutical companies and their agencies. At MDoutlook, we streamline the process to gaining precision engagement to the expertise of over 14,000 ThoughtLeaders and 120,000+ qualified treaters in oncology, hematology and rare diseases from over 120 countries. Timing is everything in
Continue Reading
Links
FDA Drug information:
http://www.fda.gov/Drugs
European Medicines Agency:
http://www.ema.europa.eu/
Publication Research:
http://www.ncbi.nlm.nih.gov/pubmed
Clinical Trials Research:
http://www.clinicaltrials.gov/